o NoneEntity Type
0001055726
INOVIO BIOMEDICAL CORP
GENETRONICS BIOMEDICAL CORP
GENETRONICS BIOMEDICAL LTD
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 INOVIO PHARMACEUTICALS, INC.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 INOVIO PHARMACEUTICALS, INC. 
Street Address 1Street Address 2
 660 W. Germantown Pike Suite 110
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 Plymouth Meeting PENNSYLVANIA 19462 2674404200 



3. Related Persons
Last NameFirst NameMiddle Name
KimJ.Jospeh
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
KiesPeter
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
BenitoSimonX.
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
CabreraAngel
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
ShepardJay
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
MillerAnnC.
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
WeinerDavidB.
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
YarnoWendyL.
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
ZothLotaS.
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HumeauLaurent
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
SheaJacqueline
Street Address 1Street Address 2
660 W. Germantown PikeSuite 110
CityState/Province/CountryZIP/Postal Code
Plymouth MeetingPENNSYLVANIA19462
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   x Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
x $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
o Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2019-12-31 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security x Other (describe)
 Convertible Bonds


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 4040590 USD o Indefinite
Total Amount Sold $ 4040590 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 Convertible bonds with an aggregate principal amount of 4.7 billion Korean Won were sold, which is approximately $4 million based on the exchange rate on the date of issuance of the bonds.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Inovio Pharmaceuticals Charts.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Inovio Pharmaceuticals Charts.

Inovio Pharmaceuticals, Inc. News

INOVIO Reports Inducement Grants Under Inducement Plan
Wednesday 1 May 2024 (3 days ago) • PR Newswire (US)
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
Monday 29 April 2024 (5 days ago) • PR Newswire (US)
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tuesday 16 April 2024 (3 weeks ago) • PR Newswire (US)
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
Wednesday 27 March 2024 (1 month ago) • PR Newswire (US)
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Thursday 7 March 2024 (2 months ago) • PR Newswire (US)
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Wednesday 6 March 2024 (2 months ago) • PR Newswire (US)
U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb
Wednesday 6 March 2024 (2 months ago) • IH Market News
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
Thursday 22 February 2024 (2 months ago) • PR Newswire (US)
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Thursday 8 February 2024 (3 months ago) • PR Newswire (US)
INOVIO Reports Inducement Grant Under Inducement Plan
Saturday 3 February 2024 (3 months ago) • PR Newswire (US)
Form EFFECT - Notice of Effectiveness
Thursday 1 February 2024 (3 months ago) • Edgar (US Regulatory)
Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
Saturday 27 January 2024 (3 months ago) • Edgar (US Regulatory)

More Inovio Pharmaceuticals, Inc. News Articles